12.03.2013 - Elan and Biogen Idec have presented a new test at AAN meeting which identifies JCV infected MS patients with good prognosis.
Whilst Tysabri (natalizumab) is the most effective treatment for relapsing multiple sclerosis, it has also its downsides: the antibody drug increases the risk of a rare but potentially fatal brain infection called progressive multifocal leukoencephalopathy (PML). A study presented at the American Academy of Neurology's 65th Annual Meeting in San Diego suggests that early detection of PML may help improve survival and disability levels of MS patients.
In the study, which was conducted by Irish Elan and Biogen Idec, 319 MS patients were treated with natalizumab and diagnosed with PML. The study compared people who had symptoms of PML at the time of diagnosis to people who had no symptoms of the infection, but who were diagnosed with the disease by brain scans and tests in the spinal fluid for the JC virus. The level of disability for the people in the study was assessed before the PML diagnosis, at the time of diagnosis, and again six months and one year after the diagnosis.
A total of 21 people had no PML symptoms at the time of their diagnosis, while 298 people did. According to preliminary findings, people without symptoms at diagnosis showed improved survival and less disability than those who had developed symptoms. As of January 1, 2013, all of the 21 people (100%) with no symptoms at the time of PML diagnosis were alive, compared to 77% of the people with symptoms at the time of diagnosis. "These results suggest that the consequences of PML infection can be mitigated by early detection of the disease," said lead investigator Dong-Si.
In mid-February, US biotech Biogen Idec had bagged full rights to Elan's Multiple Sclerosis blockbuster Tysabri in a US$3.25bn deal. Shortly after the agreement, US investor Royalty Pharma made a take-over bid but the Irish drugmaker is fighting off a possible take-over.
29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.
24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.
23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.
16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.
15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.
10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.
08.07.2015 Horizon Pharma plc. has set its sights on US-American speciality pharma company Depomed Inc. After getting nowhere with the rival’s board, Horizon has now launched a US$3bn hostile bid for the pain and CNS specialist.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more